A DEFINITIVE CASE FOR A CONTROVERSIAL THERAPEUTIC
IVM AND EARLY PROTECTION OF THE ENDOTHELIUM IN SARS-CoV-2 INFECTION
I believe I have discovered, once and for all, incontrovertible proof that IVM is an ESSENTIAL early treatment therapeutic for SARS-CoV-2 infection.
SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity and activation of monocytic THP-1 cells and cytokine responses in human blood and peripheral blood mononuclear cells. These very same activated mononuclear cells then invade the endothelium causing widespread damage, inducing a coagulation and fibrotic cascade.
In addition to the evidence of direct viral infection of endothelial cells, post-mortem histology also disclosed the presence of endothelial inflammation. Immunohistochemical analysis of lung specimens revealed staining patterns consistent with apoptotic endothelial cells and MONONUCLEAR CELL INFILTRATES.
What IVM does, is to inhibit this LPS-induced production of inflammatory cytokines, cutting the cascade off at the very beginning, disallowing the activation of mononuclear cells, thereby preventing their invasion of the endothelium.
I strongly urge all clinicians and public health officials to review this mechanism and conduct studies to determine its possible therapeutic value.
The following bodies of work should be integrated into your thesis, building your case.
Bruce Patterson's work: https://www.youtube.com/watch?v=h2xyWiMS2Q0
IVM is on the list of about 8 therapeutics that are used to address about 14 key biomarkers that were identified by AI machine learning techniques derived from a large candidate set of biomarkers taken from key groups of people with long haul type syndromes: Long Haul Post COVID, Long Haul Post COVID vaccine, Long haul ME/CFS chronic fatigue, long haul post Lyme, fibromyalgia. The results show the commonalities and differences between these syndromes. There is a key finding of persistent antigen fragments in monocytes driving COVID syndromes. Of the 14 biomarkers needed to treat, and about 8 compounds that Patterson and colleagues are focusing on, Ivermectin is one of them.
Also papers by my friend David Scheim:
(I commented on the second manuscript before it went out.)
The first talks about how a mild cold virus turned deadly by undermining a process to prevent hemagglutination. Clumping of red blood cells.
From Cold to Killer
The second paper discusses how in vitro IVM is a tool that will undo or return to healthy state the rouleaux formations in blood cells if at at their early stage. An exciting find.
A Deadly Embrace
David also published a review article on IVM for COVID with some well known folks:
Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19
Santin, Scheim, McCullough, Yagisawa, Borody
A few more papers are in the works, will keep you posted.
And the evidence mounts ... meanwhile, covid patients are told to take dangerous horse medicine. - "Molnupiravir began as a possible therapy for Venezuelan equine encephalitis virus at Emory University’s non-profit company DRIVE (Drug Innovation Ventures at Emory) in Atlanta." https://www.nature.com/articles/d41586-021-02783-1
Que narrative pivot to "just because it was originally developed for horses doesn't mean it's horse medicine", from the same gaslighters who brought us "you're not a horse, you're not a cow, seriously y'all, stop it". (Or they'll hope no one notices the equine detail .. or the mutagenic potential .. ( what could go wrong? ))